The use of imatinib (STI571) in chronic myeloid leukemia: Some practical considerations

Haematologica

Volumn 87, Issue 9, 2002, Pages 979-988

  Marin, David ^a   Marktel, Sarah ^a   Bua, Marco ^a   Armstrong, Lorraine ^a   Goldman, John M ^a   Apperley, Jane F ^a   Olavarria, Eduardo ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

CML; STI571

Indexed keywords

ALPHA INTERFERON; AMIODARONE; ANASTROZOLE; AZITHROMYCIN; CANNABINOID; CARBAMAZEPINE; CIMETIDINE; DANAZOL; DEXAMETHASONE; ENZYME INDUCING AGENT; ENZYME INHIBITOR; ETHOSUXIMIDE; GLUCOCORTICOID; GRISEOFULVIN; HYDROXYUREA; IMATINIB; METRONIDAZOLE; MIBEFRADIL; MICONAZOLE; NAFCILLIN; NEFAZODONE; NELFINAVIR; NEVIRAPINE; NORFLUOXETINE; OMEPRAZOLE; OXCARBAZEPINE; PHENOBARBITAL; PROTEIN TYROSINE KINASE INHIBITOR; SULFADIMIDINE; UNINDEXED DRUG;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG USE; DYSPEPSIA; EDEMA; FATIGUE; FEVER; HUMAN; HYPOKALEMIA; INSOMNIA; LIVER TOXICITY; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PHARMACOKINETICS; RASH; REMISSION; REVIEW; RHINOPHARYNGITIS; THROMBOCYTOPENIA; VERTIGO;

DISEASE PROGRESSION; DRUG INTERACTIONS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 0036739532     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, et al. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94:1517-36.
2. Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E, et al. Chronic myeloid leukaemia and interferon-α: a study of complete cytogenetic responders. Blood 2001; 98:3074-81.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-42.
5. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645-52.
6. Goldman JM, Druker BJ. Chronic myeloid leukemia: current treatment options. Blood 2001; 98:2039-42.
7. Druker BJ, Lydon BN. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3-7.
8. Joensuu H, Proberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
9. Apperley JF, Melo J, Cross N, Russell-Jones R, Dimetrovic S, Bain B, et al. Chronic myeloproliferative diseases involving rearrangements of the platelet derived growth factor receptor-β (PDGFRβ): rapid responses to the tyrosine kinase inhibitor STI571. 2002, Submitted for publication.
10. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
11. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90:3691-8.
12. Druker, BJ for the IRIS (International Randomized IFN vs STI571 Study Group. STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) and cytarabine as initial therapy for patients with CML: results of a randomized study. Meeting of the American Society of Clinical Oncology, Orlando FL, 2002; 21:1 [abstract].
13. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti- Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928-37.
14. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D, et al. Factors impacting on duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99:2304-9.
15. World Health Organisation classification of tumours. Jaffe SE, Harris NL, Stein H, Vardiman JW, eds. IARC Press. 2001. p. 20-6.
16. Kantarjian HM, Dixon D, Keating M. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61:1441-6.
17. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96:2712-6.
18. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86:1261-8.
19. Dazzi F, Szydlo R, Craddock C, Cross N, Kaeda J, Chase A, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67-71.
20. Olavarria E, Craddock C, Dazzi F, Marin D, Marktel S, Apperley JF, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002; 99:3861-2.
21. Kantarjian MH, O'Brien S, Cortes J, Giralt S, Rios MB, Shan J, et al. Results of imatinib mesylate (STI571) therapy in patients (pts) with chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (allo SCT). Blood 2001; 98 Suppl 11:137[abstract].
22. Chambon-Pautas C, Cony-Makhoul P, Giraudier S, Vigier M, Michallet M, Guilhot F, et al. Glivec (STI571) treatment for chronic myelogenous leukemia (CML) in relapse after allogeneic stem cell transplantation (SCT): a report of the French experience (on behalf of the SFGM and FILMC). Blood 2001; 98 Suppl 11:140[abstract].
23. Wassmann B, Pfeifer H, Scheuring U, Brueck P, Binckebank A, Atta J, et al. Glivec (STI571) in the treatment of patients with chronic myeloid leukemia (CML) relapsing in accelerated or blastic phase after allogenic stem cell transplantation. Blood 2001; 98 Suppl 140[abstract].
24. Peng B, Hayes M, Druker B. Clinical pharmacokinetics and pharmacodynamics of STI571 in a phase I trial in chronic myeloid leukemia (CML) patients. Proc Am Assoc Cancer Res 2000; 41: 256[abstract].
25. Peng B, Hayes M, Racine-Poom A, Druker B. Clinical investigation of the pharmacokinetic/pharmacodynamic relationship for Glivec (STI571): a novel inhibitor of signal transduction [abstract]. Proc Am Soc Clin Oncol 2001; 20: 280.
26. Reckmann AH, Fischer T, Peng B. Effect of food on STI571 (Glivec®) pharmacokinetics and bioavailability [abstract]. Proc Am Soc Clin Oncol 2001; 20:1223.
27. Druker JB, Ford JM. Chronic Myelogenous Leukemia. Practical aspects of STI administration. American Society of Hematology Education Program Book 2001; p. 91-7.
28. Marktel S, Bua M, Marin D, Chase A, Udom C, Armstrong L, et al. Emergence of additional chromosomal abnormalities following treatment with STI571 (imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase [abstract]. Blood 2001; 98 Supplement 11: 617.
29. Marin D, Bua M, Marktel S, Chase A, Udom C, Armstrong L, et al. The combination of cytogenetic response after 6 months treatment with STI571 and the presence of cytopenias in patients with CML in chronic phase resistant to or intolerant of interferon-α defines four different prognostic groups [abstract]. Blood 2001; 98 Supplement 11: 846.
30. Marin D, Bua M, Marktel S, Foot N, Olavarria E, Khalid G, et al. STI571 for patients with CML in chronic phase: prognostic factors for response and benefit of G-CSF [abstract]. Br J Haematol 2002; 117 Supplement 1:14.
31. Lennard AL, Clark RE, Drummond MW, Rule S, Bolam S, Marin D. Collection of peripheral blood stem cells in chronic myeloid leukaemia (CML) patients Philadelphia negative after treatment with imatinib mesylate (Glivec®) [abstract]. Br J Haematol 2002; 117 Supplement 1:14.
32. Hasserjian RP, BoecklinF, Parker S, Chase A, Dhar S, Zaiac M, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002; 117: 360-7.
33. Marin D, Marktel S, Bua M, Olavarria E, Karadimitris T, Stewart-Smith S, et al. STI571 administered in the recovery phase after autografting (auto-SCT) for CML in accelerated phase: no apparent delay in haematological recovery [abstract]. Br J Haematol 2002; 117 Suppl 1:17.
34. Olavarria E, Reiffers J, Sureda A, Meloni G, Michallet M, Clark E, et al. The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 2002; in press.
35. Giralt SA, Goldman J, Anasetti C, Cervantes F, Champlin R, Cross N, et al. Recommendations for assessment and definitions of response and relapse in CML: a report from the Chronic Leukemia Working Committee of the IBMTR. In: Chronic Myeloid Leukemia. Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R, eds. London: Martin Dunitz; 2001. p. 347-68.
36. th. Lacy CF, Armstrong LL, Goldman MP, Lance LL, eds. Hudson, OH: LexiComp Inc. 2000. p. 1364-71.